NPS: A Protein with Potential Drug-Like Properties (G594857)
NPS: A Protein with Potential Drug-Like Properties
NPS (N-Acetyl-L-Glutamate), also known as N-acetyl-L-glutamate (NALG), is a protein that is expressed in various tissues throughout the body. It is a key regulator of cellular processes, including cell signaling, neurotransmission, and stress response. NPS has also been shown to have a range of potential drug-like properties, including its ability to interact with various drug molecules and its role in modulating cellular responses to therapeutic treatments.
In addition to its potential as a drug target, NPS has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its role in these diseases, as well as its potential utility as a drug or biomarker, has made it an attractive target for researchers to investigate further.
One of the key mechanisms by which NPS functions is its role in modulating the levels of intracellular signaling molecules, such as neurotransmitters and cytokines. NPS has been shown to interact with a variety of neurotransmitters, including dopamine, serotonin, and endothelial nitric oxide (NO), among others. These interactions play a crucial role in modulating cellular responses to various stimuli and environmental factors.
In addition to its role in modulating neurotransmitter levels, NPS has also been shown to play a key role in modulating the levels of cytokines, which are proteins that are released in response to various cellular stressors, such as infection, inflammation, and physical injury. NPS has been shown to interact with cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6).
These interactions between NPS and neurotransmitters and cytokines have a range of potential implications for various diseases. For example, NPS has been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that NPS levels are often decreased in individuals with these conditions, and that these changes in NPS levels may contribute to the development and progression of the disease.
In addition to its potential role in neurodegenerative diseases, NPS has also been shown to be involved in the development and progression of other diseases, including cancer and cardiovascular diseases. For example, studies have shown that NPS levels are often decreased in individuals with certain types of cancer, such as breast cancer, and that these changes in NPS levels may contribute to the development and progression of the disease.
Furthermore, NPS has also been shown to be involved in modulating cellular responses to therapeutic treatments. For example, NPS has been shown to play a role in the development of resistance to cancer therapies, as well as in the modulation of inflammatory responses. These interactions between NPS and therapeutic treatments have significant implications for the development and effectiveness of cancer therapies.
Overall, NPS is a protein that has a range of potential drug-like properties and has been shown to play a key role in modulating cellular processes in a variety of tissues and systems. Its potential as a drug target and biomarker make it an attractive target for further research and development. As research continues to progress, NPS is likely to emerge as a promising new drug and biomarker for a variety of diseases.
Protein Name: Neuropeptide S
Functions: Modulates arousal and anxiety. May play an important anorexigenic role (By similarity). Binds to its receptor NPSR1 with nanomolar affinity to increase intracellular calcium concentrations (PubMed:15312648, PubMed:16790440)
The "NPS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPS comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
NPSR1 | NPSR1-AS1 | NPTN | NPTN-IT1 | NPTX1 | NPTX2 | NPTXR | NPVF | NPW | NPY | NPY1R | NPY2R | NPY4R | NPY4R2 | NPY5R | NPY6R | NQO1 | NQO2 | NR0B1 | NR0B2 | NR1D1 | NR1D2 | NR1H2 | NR1H3 | NR1H4 | NR1I2 | NR1I3 | NR2C1 | NR2C2 | NR2C2AP | NR2E1 | NR2E3 | NR2F1 | NR2F1-AS1 | NR2F2 | NR2F2-AS1 | NR2F6 | NR3C1 | NR3C2 | NR4A1 | NR4A2 | NR4A3 | NR5A1 | NR5A2 | NR6A1 | NRAD1 | NRADDP | NRAP | NRARP | NRAS | NRAV | NRBF2 | NRBF2P4 | NRBP1 | NRBP2 | NRCAM | NRDC | NRDE2 | NREP | NRF1 | NRG1 | NRG2 | NRG3 | NRG4 | NRGN | NRIP1 | NRIP2 | NRIP3 | NRIP3-DT | NRIR | NRK | NRL | NRM | NRN1 | NRN1L | NRON | NRP1 | NRP2 | NRROS | NRSN1 | NRSN2 | NRSN2-AS1 | NRTN | NRXN1 | NRXN2 | NRXN2-AS1 | NRXN3 | NSA2 | NSA2P2 | NSD1 | NSD2 | NSD3 | NSDHL | NSF | NSFL1C | NSFP1 | NSG1 | NSG2 | NSL complex | NSL1
